Pharmaceuticals

TJPC

TJPC released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 676.5 M, actual EPS CNY 0.0009

TJPC released FY2025 Annual Earnings on April 24 After-Market (BJT), Actual Revenue: CNY 2.908 B, Actual EPS: CNY 0.065

TJPC released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 608.11 M, actual EPS CNY 0.013

TJPC to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

TJPC FY2025 Annual Earnings Release on April 25, 2026 After-Market (BJT)

TJPC released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 643.16 M, actual EPS CNY 0.0189

TJPC released FY2025 9 Months Earnings on October 28 During-Market (BJT), actual revenue CNY 2.232 B, actual EPS CNY 0.0239

TJPC to Release FY2025 Q3 Earnings on October 29 During-Market (BJT)

TJPC released FY2025 Q2 earnings on August 22 Pre-Market (BJT), actual revenue CNY 802.61 M, actual EPS CNY -0.0079

TJPC released FY2025 Semi-Annual Earnings on August 22 Pre-Market (BJT), actual revenue CNY 1.588 B, actual EPS CNY 0.045

TJPC FY2025 Semi-Annual Earnings Release on August 23, 2025 (BJT)

Jinyao Peace PD Fluid Passes Consistency Evaluation

Tianyao Pharmaceutical Expected Net Profit Decline in First Half of 2025

Jinyao Peace Low Calcium Peritoneal Dialysis Fluid Passes Consistency Evaluation

Jinyao Pharmaceutical Increases Investment in Jiangxi Basicoconray

Jinyao Peace's Methylprednisolone Succinate Sodium for Injection Obtains Sales Permit in the Dominican Republic

TJPC released FY2025 Q1 earnings on April 28 Pre-Market BJT, actual revenue CNY 785.77 M, actual EPS CNY 0.053

TJPC FY2025 Q1 Earnings Release Scheduled for April 29, Pre-Market BJT

Jin Pharmaceutical Industry Releases 2024 Annual Report, Revenue Down 15%, Net Profit Up 14%

TJPC released FY2024 annual earnings on March 26 After-Market (BJT), actual revenue CNY 3.215 B, actual EPS CNY 0.122

600488

TJPC (600488) fell 4.91% on May 19, closing at 6 yuan, with a circulating market value of 6.551 billion yuan. The buying amount on the Dragon and Tiger List was 228 million yuan, while the selling amount was 150 million yuan, resulting in a net buying amount of 77.6786 million yuan. Among the top five buyers, the Shanghai Stock Connect special seat bought 110 million yuan. This stock was listed due to a cumulative deviation of the closing price drop reaching 20% over three consecutive trading days

同壁财经

CITIC Securities Co., Ltd.

CITIC SEC

Goldman Sachs

GUOSHENG SECURITIES

Ping An

PING AN

GUOYUAN SECURITIES

GS Hldg R

PING AN-R

Ping An Insurance

Dragon and Tiger List | TJPC (600488) fell 4.91%, with the top 5 buyers purchasing a total of 228 million yuan, and the top 5 sellers selling a total of 150 million yuan. Reason for being listed: Non-ST, *ST, and S securities have accumulated a closing price drop deviation of 20% over three consecutive trading days

301017

301584

000788

301408

600594

603222

600829

301015

603122

China's A-share pharmaceutical industry chain continues to strengthen, with Chimin and CMC hitting the daily limit, following TJPC, YIBAI PHARMACEUTICAL, and PKU HEALTHCARE also hitting the daily limit. Previously, Huaren Health, Baheal Medical, SYPM, INNOSTIC, and HRPC, among other stocks, rose more than 5%

Wallstreetcn

SYPM

C&D INNOSTIC

PKU HEALTHCARE

Huaren Health

YIBAI PHARMACEUTICAL

Chimin

HRPC

Baheal Medical

03147

510210

601872

300839

603353

At the midday close on April 2, ChiNext fell 1.78%, the Shenzhen Index dropped 1.15%, and the SSE Index declined 0.53%. The market fluctuated and adjusted, with oil and gas stocks such as BHPCC and HSPC rising against the trend, and pharmaceutical stocks active, with TJPC hitting its daily limit for five consecutive days. The shipping sector also performed strongly, with CMES hitting the daily limit and reaching a record high. Overall, losers outnumbered gainers, with over 4,200 stocks declining, and morning turnover reached 1.2 trillion yuan

CSOP CHINEXT

Fullgoal SSE Composite ETF

CMES

SSE Index

ChiNext

E Fund GEM ETF

BHPCC

Shenzhen Index

CSOP CHINEXT-R

Dacheng SZSE Component ETF

HSPC

April 2 Midday Market Review: ChiNext Falls 1.78%, Oil, Gas, and Pharmaceutical Stocks Strengthen Against Trend

002821

002361

000550

The automotive vehicle sector showed strength, with the bus segment leading the gains. Yutong Bus and SG Automotive Group both hit the daily limit, while Zhongtong Bus Holding Co.,LTD, KLM, JMC, and Ankai saw significant increases. The commercial aerospace concept continued its strong performance, with SHENJIAN GUFEN up for 4 consecutive trading days, followed by SHUNHO STOCK, Shaoyang Hydraulic, Zhongheng Design, Jullyar, and Chaojie Precision.
Innovative drug stocks were repeatedly active, with TJPC up for 3 consecutive trading days, followed by Asymchem, Biosan, Pharmaron, HITECK, and Novus Therapeutics

- On March 31, A-shares experienced fluctuations, with the Shanghai index rising by 0.45%, while the ChiNext index fell by 0.41%.  
- Hong Kong stocks opened strong but narrowed their gains, with the Hang Seng index up 0.15%.  
- The bond market showed mixed results, and commodity futures mostly declined, although metals like silver and gold increased.

Asymchem

SHENJIAN GUFEN

HITECK

SHUNHO STOCK

Ankai

SG AUTOMOTIVE GROUP

PHARMARON

Zhongtong Bus Holding Co.,LTD

Pharmaron

YTCO

Guotai CSI Bio-medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

TJPC's subsidiary, Tianjin Jiayao Heping Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the consistency evaluation of potassium hydrogen phosphate injection as a generic drug. This injection is mainly used to correct hypophosphatemia and for parenteral nutrition. Jiayao Heping submitted a supplementary application for consistency evaluation in July 2024, with a total R&D investment of approximately 9.21 million yuan

Zhitong

TJPC's subsidiary compound potassium hydrogen phosphate injection has passed the consistency evaluation of generic drugs

TJPC's subsidiary Tianjin Jiayuan Peace Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for Butorphanol Tartrate Injection issued by the National Medical Products Administration. This drug is mainly used for the treatment of cancer pain and postoperative pain, and it falls under the category of second-class psychotropic drugs. Jiayuan Peace submitted the registration application in October 2023 and received the certificate in October 2025, with a total R&D investment of approximately 22 million yuan

TJPC's subsidiary has obtained the drug registration certificate for Butorphanol Tartrate Injection

TJPC(600488.SH)

April 2 Midday Market Review: ChiNext Falls 1.78%, Oil, Gas, and Pharmaceutical Stocks Strengthen Against Trend

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

TJPC's subsidiary compound potassium hydrogen phosphate injection has passed the consistency evaluation of generic drugs

TJPC's subsidiary has obtained the drug registration certificate for Butorphanol Tartrate Injection